Amedisys Financials
AMED Stock | USD 92.64 0.07 0.08% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.43 | 0.4056 |
|
| |||||
Current Ratio | 1.22 | 1.2288 |
|
|
Investors should never underestimate Amedisys' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Amedisys' cash flow, debt, and profitability to make informed and accurate decisions about investing in Amedisys.
Net Income |
|
Amedisys | Select Account or Indicator |
Understanding current and past Amedisys Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Amedisys' financial statements are interrelated, with each one affecting the others. For example, an increase in Amedisys' assets may result in an increase in income on the income statement.
Please note, the presentation of Amedisys' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amedisys' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amedisys' management manipulating its earnings.
Amedisys Stock Summary
Amedisys competes with Acadia Healthcare, Addus HomeCare, Encompass Health, Ensign, and Option Care. Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Amedisys operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 21000 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0234361089 |
CUSIP | 023436108 |
Location | Louisiana; U.S.A |
Business Address | 3854 American Way, |
Sector | Health Care Providers & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.amedisys.com |
Phone | 225 292 2031 |
Currency | USD - US Dollar |
Amedisys Key Financial Ratios
Return On Equity | 0.0332 | ||||
Profit Margin | 0.02 % | ||||
Operating Margin | 0.08 % | ||||
Price To Sales | 1.29 X | ||||
Revenue | 2.35 B |
Amedisys Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 1.6B | 1.9B | 2.0B | 2.1B | 2.1B | 2.2B | |
Other Current Liab | 373.1M | 291.8M | 229.3M | 382.9M | 410.6M | 431.1M | |
Net Debt | 225.2M | 502.9M | 497.4M | 360.8M | 156.9M | 103.0M | |
Retained Earnings | 430.0M | 639.1M | 757.7M | 747.9M | 791.2M | 830.7M | |
Accounts Payable | 42.7M | 38.2M | 43.7M | 28.2M | 40.0M | 42.0M | |
Cash | 81.8M | 42.7M | 40.5M | 126.5M | 303.2M | 318.4M | |
Net Receivables | 255.1M | 275.0M | 296.8M | 313.4M | 296.1M | 310.9M | |
Inventory | 74.4M | 11.8M | 13.4M | 25.2M | 29.0M | 30.5M | |
Other Current Assets | 25.0M | 39.0M | 51.6M | 57.1M | 32.8M | 34.4M | |
Total Liab | 756.5M | 880.6M | 869.7M | 940.4M | 958.7M | 1.0B | |
Total Current Assets | 362.0M | 356.7M | 389.0M | 496.9M | 632.1M | 663.7M | |
Short Term Debt | 40.5M | 44.2M | 82.5M | 62.6M | 63.9M | 67.1M | |
Other Liab | 5.9M | 33.6M | 5.0M | 25.2M | 29.0M | 30.5M | |
Other Assets | 12K | 174.6M | 73.3M | 39.3M | 45.2M | 47.5M | |
Long Term Debt | 204.5M | 432.1M | 419.4M | 361.9M | 339.3M | 356.3M | |
Treasury Stock | (251.2M) | (319.1M) | (435.9M) | (461.2M) | (415.1M) | (394.3M) | |
Good Will | 932.7M | 1.2B | 1.3B | 1.2B | 1.2B | 1.3B | |
Intangible Assets | 74.2M | 111.2M | 101.2M | 102.7M | 81.2M | 65.2M | |
Net Tangible Assets | (82.8M) | (197.6M) | (375.9M) | (337.0M) | (303.3M) | (288.1M) |
Amedisys Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 11.0M | 9.5M | 22.2M | 31.3M | 30.8M | 32.3M | |
Total Revenue | 2.1B | 2.2B | 2.2B | 2.2B | 2.3B | 2.5B | |
Gross Profit | 886.2M | 980.8M | 962.8M | 990.9M | 1.0B | 1.1B | |
Operating Income | 219.3M | 251.9M | 180.8M | 156.4M | 94.5M | 50.7M | |
Ebit | 221.9M | 289.8M | 182.5M | 193.1M | 55.5M | 70.7M | |
Ebitda | 250.7M | 320.7M | 207.4M | 216.9M | 73.4M | 89.3M | |
Cost Of Revenue | 1.2B | 1.2B | 1.3B | 1.2B | 1.3B | 1.4B | |
Net Income | 183.6M | 209.1M | 118.6M | (9.7M) | 43.2M | 28.1M | |
Income Tax Expense | 25.6M | 70.1M | 42.5M | 50.6M | 48.1M | 50.5M | |
Income Before Tax | 210.8M | 280.2M | 160.2M | 39.6M | 86.2M | 47.3M | |
Minority Interest | 1.6M | 1.1M | (910K) | 1.1M | 5.1M | 5.3M | |
Tax Provision | 25.6M | 70.1M | 42.5M | 50.2M | 48.1M | 43.3M | |
Interest Income | 292K | 49K | 178K | 2.5M | 8.1M | 8.5M | |
Net Interest Income | (10.7M) | (9.5M) | (22.1M) | (26.3M) | (22.7M) | (21.5M) |
Amedisys Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | (13.1M) | (37.6M) | 8.4M | 84.7M | 164.4M | 172.6M | |
Free Cash Flow | 283.6M | 182.2M | 126.1M | 124.5M | 215.1M | 225.9M | |
Depreciation | 67.9M | 71.3M | 71.0M | 57.8M | 60.5M | 63.5M | |
Other Non Cash Items | 9.4M | (29.9M) | 9.7M | 102.6M | 45.1M | 47.3M | |
Capital Expenditures | 5.3M | 6.7M | 7.2M | 12.7M | 6.6M | 6.2M | |
Net Income | 185.2M | 210.2M | 117.7M | (9.7M) | 38.2M | 27.4M | |
End Period Cash Flow | 83.4M | 45.8M | 54.1M | 138.9M | 303.2M | 318.4M | |
Change Receivables | (24.1M) | 2.1M | (18.0M) | (14.2M) | (12.8M) | (13.4M) | |
Net Borrowings | 56.0M | (29.2M) | 230.2M | (13.3M) | (15.3M) | (16.1M) | |
Dividends Paid | 3.6B | 4.0B | 1.6M | 6.5M | 7.5M | 7.1M | |
Change To Netincome | 50.2M | 5.8M | 38.7M | 48.7M | 43.8M | 72.1M | |
Investments | 17.0M | (5.2M) | (15.6M) | 35.2M | (8.4M) | (7.9M) |
Amedisys Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amedisys's current stock value. Our valuation model uses many indicators to compare Amedisys value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amedisys competition to find correlations between indicators driving Amedisys's intrinsic value. More Info.Amedisys is rated below average in return on equity category among its peers. It is rated fourth in return on asset category among its peers reporting about 1.88 of Return On Asset per Return On Equity. At present, Amedisys' Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Amedisys by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Amedisys Systematic Risk
Amedisys' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Amedisys volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Amedisys correlated with the market. If Beta is less than 0 Amedisys generally moves in the opposite direction as compared to the market. If Amedisys Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amedisys is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amedisys is generally in the same direction as the market. If Beta > 1 Amedisys moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Amedisys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amedisys' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Amedisys growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Amedisys March 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Amedisys help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amedisys. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amedisys based on widely used predictive technical indicators. In general, we focus on analyzing Amedisys Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amedisys's daily price indicators and compare them against related drivers.
Downside Deviation | 0.5533 | |||
Information Ratio | 0.2946 | |||
Maximum Drawdown | 6.31 | |||
Value At Risk | (0.52) | |||
Potential Upside | 0.8236 |
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |